Background: “Dual triggering" for final oocyte maturation using acombination of a gonadotropin-releasing hormone agonist (GnRHa) and human chorionic gonadotropin (hCG) can improve  clinical outcomes in high responders during  in vitro fertilization–intracytoplasmic sperm injection (IVF–ICSI) GnRH-antagonist cycles. Aim of the work: To compare gonadotrophin releasing hormone agonist with low dose human chorionic gonadotrophin co-triggers versus gonadotrophin releasing hormone agonist alone for reducing the threat of severe ovarian hyperstimulation in women suffering polycystic ovarian disease correlated with outcomes. Patients and methods: There were 120 infertile women who joined the ART department at the International Islamic Center for Population Studies and Research (IICPSR) Al-Azhar University hospitals who took part in this randomised control study. Results: The difference in the number of oocytes in M1 between the groups was statistically important (p= 0.0147). As well, there was  statistically significant difference between the two groups regarding number of oocytes in M2 (p= 0.0140). Conclusion: The use of Gonadotrophin releasing hormone agonist with low dose human chorionic gonadotrophin co-triggers was not significantly  prevent the risk of mild and moderate form ovarian hyperstimulation in women suffering from polycystic ovarian disease in comparison with gonadotrophin releasing hormone agonist alone with better outcomes for dual triggering, Also, both protocols were not record any cases of severe form.